I believe the company’s ongoing efforts to lower its debt, coupled with strong cash flow generation capabilities, may enable Teva to resume dividend payments in the near future, improving the stock's appeal among investors. However, the opioid crisis, which was sparked by deceptive marketing techniques and resulted in multibillion-dollar fines for Teva, rising inflation, and the impact of the COVID-19 pandemic might all have a short-term negative influence on the stock price. Teva Pharmaceuticals (TEVA) is a generic drug manufacturer.